On Friday, Kevenue, the maker of Tylenol, saw its stocks drop more than 10% after the Wall Street Journal reported that Health and Human Services Secretary Robert F. Kennedy plans to release a federal report connecting prenatal use of Tylenol to autism. As Kennedy and his appointed vaccine panel continue to erode vaccine recommendations, many…
ACIP’s COVID vaccine workgroup to be headed by vaccine skeptic Retsef Levi
The U.S. Centers for Disease Control and Prevention chose Retsef Levi, a management and health analytics expert at MIT, to lead its COVID-19 immunization workgroup. Levi announced on X that he is “looking forward to working with colleagues… to pursue the truth through science and evidence-based approach.” Levi, one of the eight new ACIP members…
CureVac and GSK launch Phase 1 trial of mRNA-based flu vaccine
CureVac (NSDQ:CVAC) and GSK (NYSE:GSK) have announced the dosing of the first participant in a Phase 1 study of a multivalent influenza vaccine built on a second-generation mRNA backbone. The study is based in Panama and will enroll approximately 240 subjects. CVAC shares increased 2.27% to $19.34 in mid-day trading. At various points last year,…
Moderna releases positive early data for its mRNA flu vaccine; Stock tumbles
Moderna (NSDQ:MRNA) has announced positive interim data from the Phase 1 study of its quadrivalent seasonal flu vaccine candidate, mRNA-1010. Still, the results did not impress investors, as they seemed to be broadly in line with performance of Sanofi’s (NSDQ:SNY) common Fluzone HD flu vaccine. MRNA shares fell roughly 9% to $249.20 in mid-morning trading.…
Universal flu vaccine shows promise in human trial
Vaccinating against the flu is like shooting at a moving target. Influenza strains continuously mutate, and it is difficult for researchers to identify the three or four strains most likely to post the most significant risk in any given season. As a result, developing flu vaccines is something of a guessing game. According to the…